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Abstract
The importance of purinergic signaling in the intact mesolimbic–mesocortical circuit of the brain of freely moving rats is
reviewed. In the rat, an endogenous ADP/ATPergic tone reinforces the release of dopamine from the axon terminals in
the nucleus accumbens as well as from the somatodendritic region of these neurons in the ventral tegmental area, as well
as the release of glutamate, probably via P2Y1 receptor stimulation. Similar mechanisms may regulate the release of
glutamate in both areas of the brain. Dopamine and glutamate determine in concert the activity of the accumbal
GABAergic, medium-size spiny neurons thought to act as an interface between the limbic cortex and the extrapyramidal
motor system. These neurons project to the pallidal and mesencephalic areas, thereby mediating the behavioral reaction of
the animal in response to a motivation-related stimulus. There is evidence that extracellular ADP/ATP promotes goal-
directed behavior, e.g., intention and feeding, via dopamine, probably via P2Y1 receptor stimulation. Accumbal P2
receptor-mediated glutamatergic mechanisms seem to counteract the dopaminergic effects on behavior. Furthermore,
adaptive changes of motivation-related behavior, e.g., by chronic succession of starvation and feeding or by repeated
amphetamine administration, are accompanied by changes in the expression of the P2Y1 receptor, thought to modulate the
sensitivity of the animal to respond to certain stimuli.
Introduction
Extracellular nucleotides and nucleosides have been iden-
tified as important classes of signaling molecules partici-
pating in diverse functions of neuronal and non-neuronal
tissues, e.g., fast excitatory neurotransmission, nociception,
platelet aggregation and astroglial cell function [1, 2].
However, the sources of extracellular adenosine 5S-triphos-
phate (ATP) and adenosine, and the mechanisms regulating
their concentration outside the cell are not well understood.
The vesicular release of ATP which is co-stored with
classic transmitters such as acetylcholine, norepinephrine,
and serotonine [3–5], the outflow of endogenous purines in
response to neuronal activity [6–8], e.g., after activation of
postsynaptic NMDA receptors [9, 10], and the stimulation
of adenylate cyclase [11, 12] are all potential sources of
extracellular adenine nucleotides. Further, the release from
glial cells, activated immune cells or dying cells under
physiological and pathophysiological conditions contribute
to the extracellular occurrence of purines [13–15]. Once
adenine nucleotides reach the extracellular space, they are
subsequently converted to adenosine through the actions of
amultiplicityofecto-nucleotidaseenzymes[16]. Otherwise,
adenosine can be released via bi-directional nucleoside
transporters in response to different physiological stimuli
(e.g., depolarization) or directly after metabolic stress from
various cells [17, 18]. Nucleosides and nucleotides exert
their biological function by activation of cell surface P1
and P2 receptors. The P1 receptors (A1,A 2A,A 2B and A3
subtypes) exhibit relatively high affinity for adenosine in
contrast to ATP [19] and couple to G proteins, while P2
receptors have a high affinity for ADP/ATP in contrast to
adenosine [20, 21]. The P2 receptors belong either to the
P2X1,2,3,4,6,7 subclasses (ligand-gated cationic channels) or
to the P2Y1,2,4,6,11,12,13,14 subclasses (G protein-coupled
receptors) [20, 22, 23] both widely distributed in peripheral
tissues and the nervous system [24–26]. Increasing evi-
dence has been provided by in vitro experiments in the
peripheral and central nervous system that the extracellular
signaling molecules ATP as well as adenosine contribute
to the modulation of the release of, e.g., acetylcholine
[27], noradrenaline [28–31], serotonine [32, 33] and
dopamine [34]. ATP, co-released with noradrenaline from
sympathetic axon terminals, may exert a presynaptic
feedback mechanism in which released ATP modulates
the subsequent co-transmitter release [35].
Electrophysiological investigations also proved a P2
receptor-mediated release of excitatory amino acids.
Inhibitory effects of ATP on the release of glutamate were
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[36, 37]. In cultured Schwann cells [38], trigeminal mes-
encephalic nerve terminals in the brain stem [39], and
primary afferent terminals in spinal cord slice preparations
[40], ATP caused a facilitation of glutamate release. In
these in vitro studies, the non-selective P2 receptor antag-
onists PPADS and suramin both antagonized the ATP-
evoked effects.
The negative feedback regulation of transmitter release
is an inherent property of ATP [41]. The metabolic
breakdown of adenine nucleotides to adenosine, shown to
inhibit the release of various transmitters [42], may
interfere with the effects of the nucleotides themselves on
neuronal transmitter release.
Modulation of neurotransmitter release by P2 receptors
in vivo
Data on the consequences of P2 receptor stimulation on the
release of neurotransmitters in the brain in vivo,t h e
involvement of specific P2 receptor subtypes and especial-
ly on the subsequent functional outcome, e.g., on behavior,
are rare. Different reasons may contribute to this situation.
One cause may be the lack of agonists or antagonists that
discriminate with sufficient selectivity between the P2X
and P2Y receptor family or between their respective
subtypes [20]. Further, there are no compounds selective
for particular P2 receptors which are able to pass the
blood–brain barrier and therefore can be applied systemi-
cally. Additionally, ligands at P2 receptors have different
stability in the presence of degrading ecto-nucleotidases
[16, 43, 44]. This highlights the problems conflicting the
identification of P2 receptor subtypes involved in puriner-
gic signaling in vivo.
First studies on cerebral transmitter release used ATP as
the natural agonist and compared the potency order of
related structural analogs by microdialysis.
Using this approach, Zhang and co-workers [45] have
shown in the awake rat that ATP dose-dependently in-
creases the striatal extracellular level of dopamine. Struc-
tural analogs of ATP increased the striatal dopamine
concentration in the rank order of potency, 2-methylthio
ATP (2-MeSATP)9 ATPQa,b-methylene ATP9 ADP 9
AMP9 adenosine. The most potent agonist 2-MeSATP
clearly prefers P2Y1 and P2Y12 receptors compared to
ATP but has a similar potency at the P2X1 receptor; the
enzymatically stable analog a,b-methylene ATP does not
act at P2Y receptors and is most effective at P2X1 and
P2X3 receptors [46]. Hence, these data suggest that
receptors of the P2Y rather than of the P2X subtype may
be involved in the increase of extracellular dopamine
release in the striatum. The ectonucleotidase-resistant
adenosine 5S-[b,g, imido]-triphosphate caused a more
prolonged increase of the dopamine level than ATP
itself. Therefore, by their actual local activity, the
different ectonucleotidases may be strong inhibitors of
effects evoked by a rise of extracellular nucleotides. The
ATP-induced release of dopamine [45] was depressed by
the non-selective P2 receptor antagonist suramin and the
P2Y receptor antagonist reactive blue 2, but not by
xanthine amine congener, a non-selective adenosine recep-
tor antagonist. Suramin and PPADS are non-selective, but
non-universal, P2 receptor antagonists. Whereas suramin
interacts also with a large range of other proteins,
including glutamate, GABA and 5-hydroxytryptamine
receptors as well as various enzymes, PPADS is highly
specific for P2 receptors [47], e.g., without affecting
glutamate receptors [48, 49]. Further, Zhang and col-
leagues [45] have shown that the ATP-induced dopamine
release was sensitive to pertussis toxin, suggesting that a
G-protein coupled receptor is involved. The dopamine
release could be abolished by tetrodotoxin, Ca
2+-depletion
and w-conotoxin GVIA, indicating that the opening of
voltage-sensitive Na
+ channels and the Ca
2+ influx through
the N-type voltage-dependent calcium channel are both
required for these P2 receptor mediated effects. In
another study, the perfusion of the hippocampus with
ATP produced concentration-dependent changes in hip-
pocampal extracellular serotonin levels, likewise, which
consisted of an initial rise phase, followed by a later
rebound reduction phase [50]. 2-MeSATP increased the
extracellular serotonine level dramatically, while a,b-
methylene ATP produced only a slight increase.
Under special focus are studies on the physiological
importance of P2 receptor-mediated effects on the release
of various transmitters in the mesolimbic–mesocortical
system, which is relevant for the generation and expression
of motivation-related behavior. The central part of this
circuit consists of inhibitory dopaminergic projections
from neurons in the ventral tegmental area (VTA),
activated by, e.g., environmental stimuli, as well as of
excitatory corticofugal glutamatergic terminals from the
prefrontal cortex [51, 52] which target the GABAergic
medium size spiny projection neurons, the main cell type
of the nucleus accumbens (NAc) [53]. These neurons are
thought to act as an interface between the limbic cortex and
the extrapyramidal motor system, and project to pallidal
and mesencephalic regions including the VTA [54, 55].
Therefore, the modulation of accumbal activity by chang-
ing the balance of neurotransmitters or neuromodulators
could result in altered behavioral responses. In this self-
contained neuronal circuit, P2 receptors are involved in the
release of transmitters.
The administration of 2-MeSATP into the somatic or
axon terminal area of dopaminergic neurons in the VTA
and NAc, respectively, caused a dose-dependent increase
in the extracellular dopamine concentration [56–58]. In
both regions, the infusion of the P2 receptor antago-
nists reactive blue 2 or PPADS not only abolished the
2-MeSATP-induced effects but also reduced the basal
extracellular concentration of dopamine, indicating that
endogenous extracellular ATP tonically modulates the
somatodendritic dopamine release as well as that from
axon terminals.
In addition to the inhibition of various P2X receptors, the
non-selective P2 receptor antagonist PPADS acts efficiently
at the P2Y1 receptor subtype, whereas it is completely
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Other P2Y receptors are not or only slightly affected by
concentrations of PPADS higher than those used in the in
vivo studies [22, 61, 62]. It has been shown that P2Y
receptors, which are positively coupled to phospholipase C,
but not those negatively coupled to adenylate cyclase, were
inhibited by PPADS [63]. Therefore, it is tentatively
suggested that the effects of endogenous ADP/ATP on
transmitter release in the NAc may be mediated by the
activation of P2Y1 receptors leading to a stimulation of
phospholipase C, the production of inositol-1,4,5-trisphos-
phate and the mobilization of intracellular Ca
2+ resulting in
a stimulation of neuronal exocytosis. This assumption was
supported by microdialysis experiments using compounds
with higher selectivities. Since, the P2Y1 receptor is more
sensitive to adenosine nucleotide diphosphates than to
triphosphates, the P2Y1,11,12,13 receptor-selective agonist
ADPbS was infused into the NAc. ADPbSc a u s e da
concentration-dependent enhancement of dopamine in the
extracellular space of the NAc shell region. This effect was
abolished by co-perfusion with the selective P2Y1 receptor
antagonist MRS 2179 [64, 65], which also reduced the
basal dopamine concentration when given alone. ADPbS
also affects the P2Y12 receptor [66]. However, when the
selective P2Y12 receptor antagonist AR-C 69931MX [67]
was perfused together with ADPbS to eliminate the
involvement of P2Y12 receptor-mediated effects, the
amount of dopamine evoked by AR-C 69931MX alone
was additive to that evoked by ADPbS alone [68].
Therefore, a facilitatory effect of ADP/ATP on the
accumbal dopamine level by stimulation of P2Y1 receptors
can be assumed. Further, effects at of P2Y12 receptors
negatively coupled to adenylyl cyclase also seem to inhibit
the accumbal dopamine level; cyclic AMP was shown to
facilitate the release of transmitters by either protein kinase
A-dependent [69, 70] or independent pathways [71]. The
localization of P2Y1 receptor immunoreactivity within the
NAc [72] and the demonstration of mRNA expression for
the P2Y1 receptor by RT-PCR in this region [73, 74]
provide further support for the involvement of P2Y1
receptors in purinergic signaling in the mesolimbic system.
Note, that on the typical tyrosine hydroxylase-positive cells
in the VTA, an intensive P2Y1 immunoreactivity on cell
bodies as well as on their processes was found [57]. The
dopamine released from the dendrites [75, 76] might
interact with dopamine D2 receptors localized on somata
and/or dendrites of VTA neurons. This interaction may
decrease the responsiveness to afferent inputs originating
from neighboring cells [77, 78]. The modulation of the
somatodendritic dopamine release by stimulation of P2
receptors may therefore provide an indirect local inhibitory
control and fine adjustment of dopamine release. The
administration of 2-MeSATP into the VTA also caused an
increased release of dopamine from the terminals of
mesolimbic dopaminergic neurons in the NAc indicating
a stimulated firing pattern of the respective cell bodies
[57]. Therefore, P2 receptor agonists may modulate the
activity of dopaminergic cell bodies in the VTA both by
local direct stimulation and/or indirect inhibitory control
via dopamine release and subsequent dopamine D2 recep-
tor stimulation in the NAc.
Granted that ATP is co-released together with dopamine
[79–83], ATP may exert a reinforcing function on its own
effects in response to neuronal stimulation.
Electrophysiological investigations provide further evi-
dence for the facilitation of ATP effects in the mesolimbic
system. The enhanced activity of dopaminergic afferents to
the NAc induced by P2 receptor stimulation is accompa-
nied by an enhancement of the electrical activity of this
area – an elevation of the absolute EEG power and the
power in the alpha-frequency band (8–13 Hz) [84, 85]. It
has been documented that the power in the alpha-band was
also enhanced by mesolimbic neuronal and subsequent
behavioral stimulation in response to the novelty of an open
field system [84] corresponding to increased attentiveness
or vigilance [86]. The selective enhancement of the power
in the alpha-band was also observed after systemic ad-
ministration of apomorphine, quinpirole, D-amphetamine
and cocaine leading to the stimulation of dopamine D2
receptors [87, 88]. In the human EEG, the increase in the
alpha-activity is associated with enhanced intentional
behavior and hedonistic emotions [89].
In contrast to the effects of ATP in the NAc, adenosine
decreased the extracellular dopamine concentration [90,
91] and simultaneously shifted the power in the EEG
spectrum to the low frequencies, mainly to the delta band
(0.6–4.0 Hz) [85]. Increasing amounts in the delta and theta
activity correlating with a slowing in the EEG are usually
taken as a sign of either sedation [92], drowsiness and
sleep, or abnormality of brain function [93].
The functionally converse effects of 2-MeSATP and
adenosine on the extracellular concentration of dopamine
as well as on the changes in the EEG pattern in the NAc
turned into their opposite by the local administration of
the P2 receptor antagonist PPADS or the nonselective
adenosine receptor antagonist 8-(p-sulfophenyl) theophyl-
line (8-SPT), respectively. In addition to its local accumbal
effects, adenosine also slowed down the firing pattern in
the VTA neuronal population, probably by activating the
inhibitory GABAergic feedback projection from the NAc
to the VTA via stimulation of accumbal A2A receptors
[94–98]. In conclusion, the local balance between the
stimulation of adenosine- and ADP/ATP-sensitive recep-
tors seems to be determinative for the net functional
outcome at the level of transmitter release and consequent-
ly at the level of behavior [85, 99].
The idea of a purinergic modulation of the inhibitory
feedback projection is supported by the effects of low
doses of NMDA or glutamate which were shown to reduce
the basal and also the 2-MeSATP-induced dopamine
release under in vivo conditions, when the cross-talk
between NAc and VTA is intact [58]. The same study
showed that in the presence of ionotropic and metabotropic
glutamate receptor antagonists, the dopamine release
induced by 2-MeSATP was potentiated, suggesting that
P2 receptor stimulation also facilitates the release of
glutamate which, under basal conditions, inhibits the
facilitated dopamine release.
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processing of concurrent glutamate inputs to dorsal and
ventral striatal target regions [100] and that the mesolimbic
dopamine release underlies the control of purinergic
activity (see above). In the unilaterally dopamine-depleted
rat NAc, the increase of extracellular glutamate levels
evoked by 2-MeSATP exceeded that of the native NAc
fivefold. As found for dopamine, the effect of P2 receptor
stimulation on the extracellular concentration of glutamate
was dose-dependent for 2-MeSATP and ADPbS and could
be inhibited by PPADS as well as by MRS 2179 [101,
102]. Furthermore, the activation of dopamine D2 receptors
in the dopamine-depleted NAc by quinpirole decreased
the 2-MeSATP-evoked glutamate level [101]. Therefore,
the P2 receptor-mediated glutamatergic transmission in the
NAc may be processed depending on the dopaminergic
activity, likewise. However, extracellular levels of gluta-
mate monitored by microdialysis reflect the net flux
between neuronal and non-neuronal release as well as
uptake into surrounding nerve terminals and glial elements
[103, 104]. Furthermore, an ATP-evoked glutamate out-
flow by cultured astrocytes was demonstrated and has
therefore to be taken into account in this in vivo approach
[105, 106].
Modulatory role of P2 receptors in explorative
locomotor behavior
The dopaminergic and glutamatergic transmission in the
mesolimbic–mesocortical system plays a fundamental role
in facilitating the ability of motivational stimuli to elicit
behavioral activation [107]. The NAc is generally accepted
to be the main link between the limbic cortex and the
extrapyramidal motor system modulating motivation and
goal-directed locomotor activity [108]. The NAc receives a
dense mesolimbic inhibitory dopaminergic innervation
from the VTA [109] and excitatory glutamatergic afferents
from the medial prefrontal cortex [110, 111], the amygdala
and subcortical structures [53, 112, 113]. Depending on the
strength of input, the activity of the main accumbal cell
type, the GABAergic medium spiny neurons, and subse-
quently the generated motor behavior are differentially
influenced [100, 114]. Based on the above-mentioned
studies on P2 receptor-mediated transmitter release, it
may be assumed that extracellular ATP alters the behav-
ioral pattern via modulation of the neuronal activity of the
NAc and VTA. The stimulation of P2 receptors by micro-
injection of 2-MeSATP into the rat NAc was characterized
by a prolonged, more consistent and stronger directed
locomotor activity in response to the stimulus of a novel
environment [84, 115], an effect similar to that of ATP in
frog embryos [116].
Hence, the 2-MeSATP effect was indistinguishable
from the action of dopamine itself [117] or of other drugs
known to release dopamine in the NAc like amphetamine
[118]. Further, the time of increased power of the alpha-
frequency band of the EEG corresponding to enhanced
dopamine release as a response to the new environment
[119] was extended by 2-MeSATP. An inhibitory gluta-
matergic tone may be facilitated by 2-MeSATP as well,
because this substance caused a reduction rather than a
stimulation of the behavioral activity and the EEG in the
dopamine-depleted rat. This assumption is supported by
the stimulatory effects of NMDA receptor-antagonists on
locomotor behavior after systemic and striatal adminis-
tration [120]. The 2-MeSATP-induced effects on the
locomotor behavior could be abolished by PPADS and
reactive blue 2 excluding non-receptor mediated actions.
In these experiments, only reactive blue 2, but not
PPADS, enhanced the locomotor activity in the 5th to
the 10th-min interval, possibly because of the affinity of
reactive blue 2 to NMDA and APMA/kainate receptors
[48, 121]. Further, the effect of 2-MeSATP was also
abolished by the concomitant inhibition of dopamine D1
and D2/3 receptors, suggesting that the enhanced intentional
behavior after accumbal injection of an ATP analog may
be due to a P2 receptor-mediated dopamine release. Recent
studies have shown that dopamine in the NAc may be
involved in the processes that enable organisms to
overcome work-related response costs in instrumental
responding [122]. By facilitation of accumbal dopamine,
probably via P2Y1 receptors, extracellular ADP/ATP may
be involved therefore in the drive of motivation-directed
behavior.
However, the activity of the GABAergic projection
neurons terminating in the ventral pallidum [123] may be
modulated not only by activation of dopamine D1 and/or
D2/3 receptors causing a behavioral stimulation but also by
activation of glutamatergic receptors leading to an en-
hanced excitation of the GABAergic neurons with a
subsequent behavioral inhibition. Therefore, it can be
expected that the stimulation of P2 receptors by ADP/
ATP or respective agonists as well as their inhibition by
PPADS and subsequent decrease of glutamate levels may
both enhance the locomotor activity in the open-field
situation [115]. However, the pattern of movement caused
by the two pharmacological manipulations was different.
In contrast to the more goal-directed locomotor activity
evoked by 2-MeSATP or the D2 dopamine receptor agonist
quinpirole, the locomotion induced by PPADS was
characterized by a high number of direction changes, many
disruptions of movement and a higher running speed,
similar to effects caused by antagonists at the glutamater-
gic NMDA and AMPA/kainate receptors. In view of the
above-mentioned decrease of extracellular glutamate levels
[101], a reduced activation of the GABAergic projection
may be one possible pathway involved. In another study, it
has been shown that the stimulation of P2Y receptors can
facilitate NMDA-induced currents in layer V pyramidal
neurons of the rat prefrontal cortex [124]. Therefore, it is
also conceivable that PPADS in the NAc led to an
attenuation of NMDA-evoked effects and in this way to a
stimulation of the locomotor activity comparable to the
effects of glutamate receptor antagonists.
The above data show that the stimulation of P2 receptors
in the NAc may not mediate motivational behavior per se.
The administration of ADPbS into the NAc not only
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the locomotor activity in the open field which can be
blocked by the P2Y1 receptor antagonist MRS 2179 (U.
Kru ¨gel, unpublished observation). Therefore, it can be
suggest, that the degree of stimulation of P2 receptors,
probably mainly of the P2Y1 receptors, mediating the
dopaminergic and glutamatergic accumbal neurotransmis-
sion, generate different patterns of locomotion with
consequences are relevant for the drive of motivation, goal
direction and possibly to overcome anxiety. In this context,
it has to be mentioned that after application of ADPbS into
the lateral ventricle, rats showed an enhanced explorative
activity in the open arms of an elevated plus maze
indicating anxiolytic-like effects whereas MRS 2179
caused anxiogenic effects [125].
P2 receptors are also involved in adaptive changes of
motivation-related behavior after chronic stimulation of
the mesolimbic system. A repeated intra-tegmental injec-
tion of 2-MeSATP into the VTA, evoking the release of
somatodendritic dopamine, followed by exposure to the
open-field situation and a challenge with D-amphetamine
after a priming phase-induced hypersensitivity to the
behavioral effects caused by the novel environment [57].
Systemic application of D-amphetamine caused an en-
hanced locomotor activity, which could be blocked by pre-
application of PPADS into the lateral ventricle. In addition,
when PPADS was applied every time before repeated
D-amphetamine treatment, the known behavioral sensitiza-
tion was prevented, indicating the involvement of P2
receptors in the development and expression of behavioral
sensitization to D-amphetamine [126]. It has been shown
that after systemic application of D-amphetamine, diaden-
osine polyphosphates Ap4A and Ap5A and probably co-
stored ATP were released together with dopamine [127].
These polyphosphates are agonists at P2 receptors, and the
response on behavior subsequent to their stimulation may
be prevented by the given P2 receptor antagonist.
An immunohistochemical study has shown that behav-
iorally amphetamine-sensitized rats expressed an enhance-
ment of P2Y1 receptor immunoreactivity on astrocytes and
neurons as well as and astrogliosis. Both reactions were
prevented by pretreatment with PPADS, suggesting a
crucial involvement of P2Y1 receptors also in behaviorally
sensitizing processes [72].
Feeding is facilitated by endogenous ADP/ATP
in the NAc
The different pathways in the P2 receptor-mediated
regulation of the finally expressed pattern of locomotor
activity caused by endogenous or exogenous stimuli may
have consequences for feeding behavior. A decreased
anxiety and enhanced goal-direction of movements may
be suitable for the forage of the animal. For this
background that accumbal dopamine may be involved in
the threshold to spend cost in response to a rewarding
stimulus [128], ADP/ATP are thought to promote the
decision of the animal to feed via an enhancement of
accumbal extracellular dopamine. Previous studies [129,
130] have shown that dopamine release is increasing
during feeding. This finding agrees with changes in the
simultaneously recorded EEG to an enhanced power in the
alpha-frequency band in the initial phase of the feeding
both in the NAc and VTA [131]. The EEG changes in the
VTA correlate with the somatodendritic dopamine release
in the cell body region during feeding, showing that the
mesolimbic pathway is activated by ingestive behavior
[132].
Our group [133] could show by microdialysis experi-
ments that the inhibition of accumbal P2 receptors by
PPADS suppressed not only the feeding-evoked release of
dopamine but also the amount and duration of food intake.
It is suggested that in a situation when the stimulation of
dopamine D1 and D2/3 receptors is low because of a
PPADS-induced decrease in basal dopamine release, the
impetus to take the presented food is reduced. Therefore,
the efficiency of stimulation of P2 receptors has to be
considered as an important trigger for feeding. The
inhibition of P2 receptors by PPADS may lead to a
predominance of adenosinergic mechanisms possibly re-
sponsible for the suppression of feeding-induced dopamine
release and neuronal activity. Both effects were eliminated
by the non-selective adenosine receptor antagonist 8-STP
[131]. The inhibition of the multisynaptic inhibitory
feedback projection to the VTA [134] by 8-SPT was
shown to enhance extracellular dopamine levels [135] and
to enhance feeding by inhibiting adenosine A2A receptors
[136]. P2 receptors of the P2Y1 receptor-subtype may
represent the main pathway in the purinergic facilitation of
feeding. Whereas the P2X receptor preferring agonist a,b-
methylene ATP had no effect on the amount of food intake
and duration of ingestion behavior, both parameters were
enhanced by administration of ADPbS into the lateral
ventricle of rats and could be abolished by co-application
of PPADS [137].
However, the expression of a certain motivation-related
behavior seems to be also determined by the balance of the
dopaminergic and glutamatergic input to accumbal GABA
neurons [100] as was reported for intentional locomotion.
It has been repeatedly shown [138, 139] that glutamate
antagonists elicit intense feeding in satiated rats mainly by
inhibiting NMDA and non-NMDA receptors in the NAc
region. Therefore, the local reduction of extracellular
glutamate levels by PPADS [101] may have direct effects
on the ingestive behavior. Using P2Y receptor antagonists
as pharmacological tools in intact neuronal circuits,
functional glutamate antagonistic effects, probably depend-
ing on the used dose and the basic level of Fmood`, may
facilitate the behavioral response to a motivation-related
stimulus.
It has been shown that repeated food restriction – the suc-
cession of malnutrition (Fhunger`) and re-feeding – leads
to sensitization [140, 141]. These experimental conditions
imitate the sequence of events occurring during different
human eating disorders [142]. In such a restricted feeding
model for rats the P2Y1 receptor mRNA was initially
reduced, possibly related to the aversive or stressor effects
P2 receptors and behavior 25of the impaired energy balance [73]. However, a long-
lasting food deprivation caused an increase of the P2Y1
receptor mRNA in the accumbal region, thought to be a
reflection of reduced stimulation of P2 receptors, in
correlation to the reported reduced accumbal release of
dopamine in food deprived rats [140]. It can be assumed
that these adaptive changes in the P2 receptor expression
are aimed to enhance the sensitivity of these receptors to
respond to motivation-related stimuli like food.
Conclusions
In conclusion, P2 receptors of the mesolimbic–mesocor-
tical system, probably of the P2Y1 subtype, are involved in
the release of various neurotransmitters, e.g., of dopamine
and glutamate. Changes in the extracellular concentrations
of these neurotransmitters are at least partly responsible for
the generation and pattern of the behavioral outcome after
motivation-related stimuli. Summarizing the presented
data, ADP/ATP-evoked glutamate release in the NAc
may contribute to a limitation of the urge to respond to a
dopamine-supported stimulation of goal-directed behavior.
Furthermore, there is a functionally relevant balance
between extracellular ADP/ATP and adenosine levels.
Changes in the degree of the stimulation of their re-
spective receptors cause a predominance of motivationally
stimulatory (e.g., via P2Y1 receptors) or depressant effects
(via adenosine receptors) effects. Adaptive changes of
motivation-related behavior, e.g., by chronic succession of
starvation and feeding or by repeated amphetamine
administration, are accompanied by changes in the expres-
sion of the P2Y1 receptor, thought to modulate the
sensitivity of the animal to respond to certain stimuli.
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